TY - JOUR
T1 - LMO2 is a novel predictive marker for a better prognosis in pancreatic cancer
AU - Nakata, Kohei
AU - Ohuchida, Kenoki
AU - Nagai, Eishi
AU - Hayashi, Akifumi
AU - Miyasaka, Yoshihiro
AU - Kayashima, Tadashi
AU - Yu, Jun
AU - Aishima, Shinichi
AU - Oda, Yoshinao
AU - Mizumoto, Kazuhiro
AU - Tanaka, Masao
AU - Tsuneyoshi, Masazumi
N1 - Funding Information:
Abbreviations: LMO2, LIM domain only 2; qRT-PCR, quantitative reverse transcription– polymerase chain reaction; PanIN, pancreatic intraepithelial neoplasia; IDC, invasive ductal carcinoma; FFPE, formalin-fixed paraffin-embedded; DLBCL, diffuse large B-cell lymphoma; PIN, prostatic intraepithelial neoplasia Address all correspondence to: Eishi Nagai, MD, PhD, Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan. E-mail: eishi@surg1.med.kyushu-u.ac.jp 1Supported by a Grant-in-Aid from the Ministry of Education, Culture, Sports, Science, and Technology of Japan. Received 3 March 2009; Revised 5 April 2009; Accepted 5 April 2009 Copyright © 2009 Neoplasia Press, Inc. All rights reserved 1522-8002/09/$25.00 DOI 10.1593/neo.09418
PY - 2009/7
Y1 - 2009/7
N2 - PURPOSE: LIM domain only 2 (LMO2) has been identified as a novel oncogene associated with carcinogenesis and better prognosis in several malignant tumors. We investigate the involvement of LMO2 in pancreatic cancer. EXPERIMENTAL DESIGN: We evaluated LMO2 expression in cultured cells, bulk tissues, and microdissected cells from pancreatic cancers by quantitative reverse transcription-polymerase chain reaction and immunohistochemistry. RESULTS: Of 164 pancreatic cancers, 98 (60%) were positive for LMO2 expression. LMO2 was more frequently detected in high-grade pancreatic intraepithelial neoplasia (PanIN) lesions (PanIN-2 and -3) than in low-grade PanIN lesions (PanIN-1A and -1B; P < .001) and was not detected in normal pancreatic ductal epithelium. The LMO2 messenger RNA levels were significantly higher in invasive ductal carcinoma cells than in normal pancreatic cells as evaluated by quantitative reverse transcription-polymerase chain reaction analyses of microdissected cells (P = .036). We also found higher incidence of LMO2 expression in histologic grade G1/G2 cancers than in grade G3 cancers (P < .001). The median survival time of LMO2-positive patients was significantly longer than that of LMO2-negative patients (P < .001), and multivariate analyses revealed that high LMO2 expression was an independent predictor of longer survival (risk ratio, 0.432, P < .001). Even among patients with a positive operative margin, LMO2-positive patients had a significant survival benefit compared with LMO2-negative patients. We further performed a large cohort study (n = 113) to examine the LMO2 messenger RNA levels in formalin-fixed paraffin-embedded samples and found similar results. CONCLUSIONS: LMO2 is a promising marker for predicting a better prognosis in pancreatic cancer.
AB - PURPOSE: LIM domain only 2 (LMO2) has been identified as a novel oncogene associated with carcinogenesis and better prognosis in several malignant tumors. We investigate the involvement of LMO2 in pancreatic cancer. EXPERIMENTAL DESIGN: We evaluated LMO2 expression in cultured cells, bulk tissues, and microdissected cells from pancreatic cancers by quantitative reverse transcription-polymerase chain reaction and immunohistochemistry. RESULTS: Of 164 pancreatic cancers, 98 (60%) were positive for LMO2 expression. LMO2 was more frequently detected in high-grade pancreatic intraepithelial neoplasia (PanIN) lesions (PanIN-2 and -3) than in low-grade PanIN lesions (PanIN-1A and -1B; P < .001) and was not detected in normal pancreatic ductal epithelium. The LMO2 messenger RNA levels were significantly higher in invasive ductal carcinoma cells than in normal pancreatic cells as evaluated by quantitative reverse transcription-polymerase chain reaction analyses of microdissected cells (P = .036). We also found higher incidence of LMO2 expression in histologic grade G1/G2 cancers than in grade G3 cancers (P < .001). The median survival time of LMO2-positive patients was significantly longer than that of LMO2-negative patients (P < .001), and multivariate analyses revealed that high LMO2 expression was an independent predictor of longer survival (risk ratio, 0.432, P < .001). Even among patients with a positive operative margin, LMO2-positive patients had a significant survival benefit compared with LMO2-negative patients. We further performed a large cohort study (n = 113) to examine the LMO2 messenger RNA levels in formalin-fixed paraffin-embedded samples and found similar results. CONCLUSIONS: LMO2 is a promising marker for predicting a better prognosis in pancreatic cancer.
UR - http://www.scopus.com/inward/record.url?scp=67650501096&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=67650501096&partnerID=8YFLogxK
U2 - 10.1593/neo.09418
DO - 10.1593/neo.09418
M3 - Article
C2 - 19568416
AN - SCOPUS:67650501096
VL - 11
SP - 712
EP - 719
JO - Neoplasia
JF - Neoplasia
SN - 1522-8002
IS - 7
ER -